PriceTargets.com logo

Outset Medical - OM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.42
  • Forecasted Upside: 112.42%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.55 As of 04/24/2024 01:00 AM ET
▲ +0.09 (3.66%)

This chart shows the closing price for OM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Outset Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OM

Analyst Price Target is $5.42
▲ +112.42% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Outset Medical in the last 3 months. The average price target is $5.42, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 112.42% upside from the last price of $2.55.

This chart shows the closing price for OM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Outset Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2024BTIG ResearchInitiated CoverageBuy$6.00Low
4/5/2024CL KingUpgradeNeutral ➝ Buy$6.00Low
1/12/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$14.00 ➝ $6.00Low
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$5.00 ➝ $5.50Low
11/14/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$19.00 ➝ $5.00Low
10/13/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$29.00 ➝ $17.00Low
10/13/2023Stifel NicolausLower TargetBuy ➝ Buy$26.00 ➝ $6.00Low
10/13/2023Bank of AmericaReiterated RatingBuy ➝ Underperform$32.00 ➝ $3.00Low
8/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$22.00 ➝ $19.00Low
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00Low
8/17/2023CL KingInitiated CoverageNeutralLow
8/3/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$23.00 ➝ $22.00Low
5/31/2023888Reiterated RatingMaintainsLow
1/6/2023Morgan StanleyBoost TargetEqual Weight$17.00 ➝ $27.00Low
11/15/2022CowenLower Target$22.00N/A
11/11/2022Royal Bank of CanadaInitiated CoverageOutperform$23.00Low
11/10/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $17.00Low
11/9/2022The Goldman Sachs GroupLower TargetBuy$34.00 ➝ $29.00Low
11/9/2022CowenLower Target$33.00 ➝ $22.00Low
11/9/2022CowenLower Target$33.00 ➝ $22.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $19.00Low
8/3/2022The Goldman Sachs GroupLower TargetBuy$48.00 ➝ $34.00Low
8/2/2022Morgan StanleyBoost TargetEqual Weight$20.00 ➝ $22.00Low
7/18/2022Stifel NicolausLower Target$30.00 ➝ $24.00Low
7/14/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$48.00 ➝ $20.00Low
6/14/2022CowenLower TargetOutperform$60.00 ➝ $33.00High
6/14/2022CowenLower Target$60.00 ➝ $33.00High
6/14/2022Stifel NicolausLower Target$55.00 ➝ $30.00High
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyHigh
2/17/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$55.00 ➝ $50.00High
2/17/2022CowenLower Target$70.00 ➝ $60.00High
8/18/2021CowenInitiated CoverageOutperform$70.00High
8/9/2021Morgan StanleyLower TargetEqual Weight$60.00 ➝ $55.00High
5/6/2021Morgan StanleyBoost TargetEqual Weight$58.00 ➝ $60.00High
4/19/2021Wells Fargo & CompanyInitiated CoverageOverweight$63.00Low
3/10/2021Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $58.00Low
12/16/2020OppenheimerInitiated CoverageMarket PerformLow
12/15/2020OppenheimerInitiated CoverageMarket PerformMedium
12/15/2020Morgan StanleyBoost TargetEqual Weight$48.00 ➝ $52.00Low
10/12/2020BarclaysInitiated CoverageOverweightHigh
10/12/2020Morgan StanleyInitiated CoverageEqual Weight$48.00Low
10/12/2020Stifel NicolausInitiated CoverageBuy$54.00Low
10/12/2020SVB LeerinkInitiated CoverageMarket Perform$60.00Low
10/12/2020Bank of AmericaInitiated CoverageBuyLow
10/12/2020The Goldman Sachs GroupInitiated CoverageBuy$54.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Outset Medical logo
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Read More

Today's Range

Now: $2.55
Low: $2.41
High: $2.61

50 Day Range

MA: $2.58
Low: $1.94
High: $3.79

52 Week Range

Now: $2.55
Low: $1.92
High: $24.13

Volume

769,560 shs

Average Volume

1,032,868 shs

Market Capitalization

$131.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Outset Medical?

The following sell-side analysts have issued research reports on Outset Medical in the last year: 888 Holdings plc, Bank of America Co., BTIG Research, CL King, Morgan Stanley, Royal Bank of Canada, and Stifel Nicolaus.
View the latest analyst ratings for OM.

What is the current price target for Outset Medical?

6 Wall Street analysts have set twelve-month price targets for Outset Medical in the last year. Their average twelve-month price target is $5.42, suggesting a possible upside of 112.4%. Stifel Nicolaus has the highest price target set, predicting OM will reach $6.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $3.00 for Outset Medical in the next year.
View the latest price targets for OM.

What is the current consensus analyst rating for Outset Medical?

Outset Medical currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OM, but not buy more shares or sell existing shares.
View the latest ratings for OM.

What other companies compete with Outset Medical?

Other companies that are similar to Outset Medical include Electromed, FONAR, Vivani Medical, Semler Scientific and Hyperfine. Learn More about companies similar to Outset Medical.

How do I contact Outset Medical's investor relations team?

Outset Medical's physical mailing address is 3052 ORCHARD DRIVE, SAN JOSE CA, 95134. The company's listed phone number is 669-231-8200 and its investor relations email address is [email protected]. The official website for Outset Medical is outsetmedical.com. Learn More about contacing Outset Medical investor relations.